Table of Contents
1.1 Objectives of this Document
SECTION 2 – GENERAL TERM SELECTION PRINCIPLES
2.4 Always Select a Lowest Level Term
2.5 Select Only Current Lowest Level Terms
2.7 Use of Medical Judgment in Term Selection
2.8 Selecting More than One Term
2.10 Select Terms for All Reported Information, Do Not Add Information
SECTION 3 – TERM SELECTION POINTS
3.1 Definitive and Provisional Diagnoses with or without Signs and Symptoms
3.2 Death and Other Patient Outcomes
3.2.2 Death as the only reported information
3.2.3 Death terms that add important clinical information
3.2.4 Other patient outcomes (non-fatal)
3.3.2 If self-injury is reported
3.4 Conflicting/Ambiguous/Vague Information
3.5.1 Diagnosis and sign/symptom
3.5.2 One reported condition is more specific than the other
3.5.3 A MedDRA combination term is available
3.5.4 When to “split” into more than one MedDRA term
3.5.5 Event reported with pre-existing condition
3.6.1 MedDRA term includes age and event information
3.6.2 No available MedDRA term includes both age and event information
3.7 Body Site vs. Event Specificity
3.7.1 MedDRA term includes body site and event information
3.7.2 No available MedDRA term includes both body site and event information
3.7.3 Event occurring at multiple body sites
3.8 Location-Specific vs. Microorganism-Specific Infection
3.8.1 MedDRA term includes microorganism and anatomic location
3.8.2 No available MedDRA term includes both microorganism and anatomic location
3.9 Modification of Pre-existing Conditions
3.10 Exposures during Pregnancy and Breast Feeding
3.10.2 Events in the child or foetus
3.11.2 Acquired conditions (not present at birth)
3.11.3 Conditions not specified as either congenital or acquired
3.12.1 Do not infer malignancy
3.13 Medical and Surgical Procedures
3.13.1 Only the procedure is reported
3.13.2 Procedure and diagnosis are reported
3.14.1 Results of investigations as ARs/AEs
3.14.2 Investigation results consistent with diagnosis
3.14.3 Investigation results not consistent with diagnosis
3.14.4 Grouped investigation result terms
3.14.5 Investigation terms without qualifiers
3.15 Medication Errors, Accidental Exposures and Occupational Exposures
3.15.1.1 Medication errors reported with clinical consequences
3.15.1.2 Medication errors and potential medication errors reported without clinical consequences
3.15.1.3 Medication monitoring errors
3.15.1.4 Do not infer a medication error
3.15.2 Accidental exposures and occupational exposures
3.16 Misuse, Abuse and Addiction
3.17 Transmission of Infectious Agent via Product
3.18 Overdose, Toxicity and Poisoning
3.18.1 Overdose reported with clinical consequences
3.18.2 Overdose reported without clinical consequences
3.19.1 Device-related event reported with clinical consequences
3.19.2 Device-related event reported without clinical consequences.
3.20.1 Reporter specifically states an interaction
3.20.2 Reporter does not specifically state an interaction
3.21 No Adverse Effect and “Normal” Terms
3.22 Unexpected Therapeutic Effect
3.23.2 Do not infer lack of effect
3.23.3 Increased, decreased and prolonged effect
3.24.1 Use of terms in this SOC
3.24.2 Illegal acts of crime or abuse
3.25 Medical and Social History
3.26 Indication for Product Use
3.26.3 Indications with genetic markers or abnormalities
3.26.4 Prevention and prophylaxis
3.26.5 Procedures and diagnostic tests as indications
3.26.6 Supplementation and replacement therapies
3.26.7 Indication not reported
3.27.1 Off label use when reported as an indication
3.27.2 Off label use when reported with an AR/AE
3.28.1 Product quality issue reported with clinical consequences
3.28.2 Product quality issue reported without clinical consequences.
3.28.3 Product quality issue vs. medication error
4.1.1 Versioning methodologies
MedDRA® TERM SELECTION:
POINTS TO CONSIDER
ICH-Endorsed Guide for MedDRA Users
Release 4.24
March 2024
Disclaimer and Copyright Notice
This document is protected by copyright and may, with the exception of the MedDRA and ICH logos, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the document is acknowledged at all times. In case of any adaption, modification or translation of the document, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original document. Any impression that the adaption, modification or translation of the original document is endorsed or sponsored by the ICH must be avoided.
The document is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original document be liable for any claim, damages or other liability arising from the use of the document.
The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.
MedDRA® trademark is registered by ICH
The Medical Dictionary for Regulatory
Activities terminology (MedDRA) was designed for sharing regulatory
information for human medical products. In order for MedDRA
to harmonise the exchange of coded data, users should be consistent in the
assignment of terms to verbatim reports of symptoms, signs, diseases, etc.
This MedDRA Term Selection: Points to Consider (MTS:PTC) document is an ICH-endorsed guide for MedDRA users. It is updated annually in step with the March
release of MedDRA (starting with MedDRA
Version 23.0) and is support documentation for MedDRA.
It was developed and is maintained by a working group charged by the ICH
Management Committee. The working group consists of representatives of ICH
regulatory and industry members, the World Health Organization, the MedDRA Maintenance and Support Services Organization
(MSSO), and the Japanese Maintenance Organization (JMO) (see the M1 MedDRA Terminology page under Multidisciplinary Guidelines on the ICH website for a list of
current members).
In addition, the working group has developed a
condensed version of the MTS:PTC document which focuses
on the fundamental principles of term selection and is intended to support the
implementation and use of MedDRA in the ICH regions
and beyond (see Appendix, Section 4.2). It is available in all MedDRA languages except for English, Japanese, and other
languages with an available translation of the full MTS:PTC
document. The full MTS:PTC document in its various
translations will continue to be maintained and updated as the complete
reference document.
The objective
of the MTS:PTC document is to promote accurate and consistent term selection.
Organisations
are encouraged to document their term selection methods and quality assurance
procedures in organisation-specific coding guidelines which should be consistent
with the MTS:PTC.
Consistent
term selection promotes medical accuracy for sharing MedDRA-coded
data and facilitates a common understanding of shared data among academic,
commercial and regulatory entities. The MTS:PTC could
also be used by healthcare professionals, researchers, and other parties
outside of the regulated biopharmaceutical industry.
The
document provides term selection considerations for business purposes and
regulatory requirements. There may be examples that do not reflect practices and
requirements in all regions. This document does not specify regulatory
reporting requirements, nor does it address database issues. As experience with
MedDRA increases, and as MedDRA
changes, there will be revisions to this document.
Term selection for adverse reactions/adverse
events (ARs/AEs), device-related events, product quality issues, medication
errors, exposures, medical history, social history, investigations, misuse and
abuse, off label use, and indications is addressed in this MTS:PTC document.
MedDRA's
structure allows for aggregation of those reported terms in medically
meaningful groupings to facilitate analysis of safety data. MedDRA
can also be used to list AR/AE data in reports (tables, line listings, etc.),
compute frequencies of similar ARs/AEs, and capture and analyse related data
such as product indications, investigations, and medical and social history.
The MTS:PTC document does not address every potential term
selection situation. Medical judgment and common sense should also be applied.
This
document is not a substitute for MedDRA training. It
is essential for users to have knowledge of MedDRA's
structure and content. For optimal MedDRA term
selection, one should also refer to the MedDRA Introductory
Guide (see Appendix, Section 4.2).
Users are
invited to contact the MSSO Help Desk with any questions or comments
about this MTS:PTC document.
In some
cases, where there is more than one option for selecting terms, a preferred
option is identified in this document. Designation
of a preferred option does not limit MedDRA users
to applying that option. Users should always first consider regional
regulatory requirements. An organisation should be consistent in the option
that they choose to use and document that option in internal coding guidelines.
The MSSO
provides browsers (the Desktop, Web-Based, and Mobile browsers) that allow for
searching and viewing the terminology (see Appendix, Section 4.2). Users may
find these browsers useful aids in term selection.
The quality
of the original reported information directly impacts the quality of data output.
Clarification should be obtained for data that are ambiguous, confusing, or
unintelligible. If clarification cannot be obtained, refer to Section 3.4.
To promote
consistency, organisations should document their term selection methods and
quality assurance procedures in coding guidelines consistent with this MTS:PTC document.
Clear
initial data can be promoted through careful design of data collection forms,
and training of individuals in data collection and follow-up (e.g., investigators,
drug sales representatives).
Term
selection should be reviewed by a qualified individual, i.e., a person with
medical background or training who has also received MedDRA
training.
Human
oversight of term selection performed by IT tools (such as an autoencoder) is needed to assure that the end result fully
reflects the reported information and makes medical sense.
For further
information, please refer to Section 2 of the MedDRA
Points to Consider Companion Document which contains detailed examples and
guidance on data quality (see Appendix, Section 4.2).
MedDRA is
a standardised terminology with a
pre-defined term hierarchy that should not be altered. Users must not make ad hoc
structural alterations to MedDRA, including changing
the primary SOC allocation; doing so would compromise the integrity of this
standard. If terms are found to be incorrectly placed in the MedDRA hierarchy, a change request should be submitted to
the MSSO.
Example
Change Request to Re-Assign Primary SOC |
In a previous version of MedDRA,
PT Factor VIII deficiency was
incorrectly assigned to primary SOC Blood
and lymphatic system disorders. By means of a Change Request, the PT was
re-assigned to primary SOC Congenital,
familial and genetic disorders (making SOC Blood and lymphatic system disorders its secondary SOC
assignment). |
MedDRA
Lowest Level Term(s) (LLT) that most
accurately reflects the reported verbatim information should be selected.
The degree
of specificity of some MedDRA LLTs may be challenging
for term selection. Here are some tips for specific instances:
Example
Reported |
LLT Selected |
Lip sore |
Lip sore (PT Lip pain) |
Lip sores |
Sores lip (PT Cheilitis) |
Sore gums |
Sore gums (PT Gingival pain) |
Sores gum |
Sores gum (PT Noninfective gingivitis) |
MedDRA generally
excludes terms with demographic descriptors (age, gender, etc.), but some terms
with gender qualifiers are included if the gender renders the concept unique.
Example
Distinct Gender-Specific Terms |
In MedDRA, there
are separate LLTs/PTs for Infertility, Infertility female and Infertility
male |
Organisation-specific
coding guidelines should address instances when it is important to capture
gender-specific concepts.
MedDRA
users should also consider the impact of gender-specific terms when comparing
current data to data coded with a legacy terminology in which such gender
specificity may not have been available.
Example
Gender Specificity Legacy Terms vs. MedDRA |
Consider the impact of selecting gender-specific
MedDRA terms for breast cancer (e.g., LLT Breast cancer female) when comparing
data coded in a legacy terminology with only a single Breast cancer term. |
MedDRA
contains some postoperative and post procedural terms. Select the most
specific term available.
Example
Reported |
LLT Selected |
Bleeding after surgery |
Bleeding postoperative |
Sepsis occurred after the procedure |
Post procedural sepsis |
More specific
LLTs may be available in a new version of MedDRA. See
Appendix, Section 4.2.
Non-current
LLTs should not be used for term selection.
Do not
address deficiencies in MedDRA with organisation-specific
solutions. If there is no MedDRA term available to
adequately reflect the reported information, submit a change request to MSSO.
Example
Change Request for a New Term |
LLT HBV
coinfection was added to MedDRA following a
user's request. |
If an exact
match cannot be found, medical judgment
should be used to adequately represent the medical concept with an existing MedDRA term.
When a
specific medical concept is not represented by a single MedDRA term, consider requesting a
new term through the change request process (see Section 2.6). Whilst waiting
for the new term, select one or more existing terms using a consistent approach
with careful consideration of the impact on data retrieval, analysis, and
reporting.
In some
cases, it may be appropriate to select more than one MedDRA
LLT to represent the reported information. If only one term is selected,
specificity may be lost; on the other hand, selecting more than one term may
lead to redundant counts. Established procedures should be documented.
Example
More Than One LLT
Selected |
There is no single MedDRA
term for metastatic gingival cancer . Therefore,
the options are:
|
When
considering selecting an LLT, check the hierarchy above the LLT (PT level and
further up the hierarchy to HLT, HLGT and SOC) to ensure the placement accurately
reflects the meaning of the reported term.
Select
terms for every AR/AE reported, regardless of causal association. In addition,
select terms for device-related events, product quality issues, medication
errors, medical history, social history, investigations, and indications as
appropriate.
If a
diagnosis is reported with characteristic signs and symptoms, the preferred option is to select a term
for the diagnosis only (see Section 3.1 for details and examples).
When
selecting terms, no reported information should be excluded from the term
selection process; similarly, do not add information by selecting a term for a
diagnosis if only signs or symptoms are reported.
Example
Reported |
LLT Selected |
Comment |
Abdominal pain, increased serum amylase, and increased serum lipase |
Abdominal pain |
It is inappropriate to assign an LLT for
diagnosis of pancreatitis |
Serum amylase increased |
||
Lipase increased |
The table
below provides term selection options for definitive and provisional diagnoses
with or without signs/symptoms reported. Examples are listed below the table.
A
provisional diagnosis may be described as suspicion of , probable ,
presumed , likely , rule out , questionable , differential , etc.
The preferred option for a single or
multiple provisional diagnosis(es)
is to select a term(s) for the diagnosis(es) and terms for reported signs and
symptoms. This is because a provisional diagnosis may change while
signs/symptoms do not.
SUMMARY OF PREFERRED
AND ALTERNATE OPTIONS |
|
SINGLE DIAGNOSIS |
|
DEFINITIVE DIAGNOSIS |
PROVISIONAL
DIAGNOSIS |
Single definitive
diagnosis
|
Single provisional
diagnosis
|
Single definitive
diagnosis
Note: Always include signs/symptoms not associated with diagnosis SEE EXAMPLE 1 |
Single provisional
diagnosis
Note: Always include signs/symptoms not associated with diagnosis SEE EXAMPLE 2 |
MULTIPLE DIAGNOSES |
|
DEFINITIVE DIAGNOSES |
PROVISIONAL
DIAGNOSES |
Multiple definitive
diagnoses
|
Multiple provisional
diagnoses
|
Multiple definitive
diagnoses
Note: Always include signs/symptoms not associated with diagnosis SEE EXAMPLE 3 |
Multiple provisional
diagnoses
Note: Always include signs/symptoms not associated with diagnosis SEE EXAMPLE 4 |
EXAMPLES |
|||
Example |
Reported |
LLT Selected |
Preferred Option |
Anaphylactic
reaction, rash dyspnoea, hypotension, |
Anaphylactic reaction |
|
|
Anaphylactic reaction Rash Dyspnoea Hypotension Laryngospasm |
|
||
Possible
myocardial infarction with chest pain, |
Myocardial infarction Chest pain Dyspnoea Diaphoresis |
|
|
Chest pain Dyspnoea Diaphoresis |
|
||
Pulmonary embolism Myocardial infarction Congestive heart failure |
|
||
Pulmonary embolism Myocardial infarction Congestive heart failure Chest pain Cyanosis Shortness of breath Blood pressure decreased |
|
||
Pulmonary embolism Myocardial infarction Congestive heart failure Chest pain Cyanosis Shortness of breath Blood pressure decreased |
|
||
Chest pain Cyanosis Shortness of breath Blood pressure decreased |
|
||
Always include signs/ symptoms not associated with diagnosis |
Myocardial infarction, chest pain, dyspnoea,
diaphoresis, ECG changes and jaundice |
Myocardial infarction Jaundice (note that jaundice is not typically
associated with myocardial infarction) |
|
Death,
disability, and hospitalisation are considered outcomes in the context of safety reporting and not usually considered
ARs/AEs. Outcomes are typically recorded in a separate manner (data field) from
AR/AE information. A term for the outcome should be selected if it is the only
information reported or provides significant clinical information.
(For
reports of suicide and self-harm, see Section 3.3).
Death is an
outcome and not usually considered an AR/AE. If ARs/AEs are reported along with
death, select terms for the ARs/AEs. Record the fatal outcome in an appropriate
data field.
Example
Reported |
LLT Selected |
Comment |
Death due to myocardial infarction |
Myocardial infarction |
|
Constipation, ruptured bowel, peritonitis,
sepsis; patient died |
Constipation Perforated bowel Peritonitis Sepsis |
If the only
information reported is death, select the most specific death term available.
Circumstances of death should not be inferred but recorded only if stated by
the reporter.
Death terms
in MedDRA are linked to HLGT Fatal
outcomes.
Example
Reported |
LLT Selected |
Patient was found dead |
Found dead |
Patient died in childbirth |
Maternal death during childbirth |
The autopsy report stated that the cause of
death was natural |
Death from natural causes |
Death terms
that add important clinical information should be selected along with any
reported ARs/AEs.
Example
Reported |
LLT Selected |
Patient experienced a rash and had sudden
cardiac death |
Rash Sudden cardiac death |
Hospitalisation,
disability, and other patient outcomes are not generally considered ARs/AEs.
Example
Reported |
LLT Selected |
Comment |
Hospitalisation due to congestive heart
failure |
Congestive heart failure |
Record hospitalisation as an outcome |
If the only
information reported is the patient outcome, select the most specific term
available.
Example
Reported |
LLT Selected |
Patient was hospitalised |
Hospitalisation |
Accurate
and consistent term selection for reports of suicide attempts, completed
suicides, and self-harm is necessary for data retrieval and analysis. If the
motive for reported injury is not clear, seek clarification from the source.
Do not
assume that an overdose including an intentional overdose is a suicide
attempt. Select only the appropriate overdose term (see Section 3.18).
For reports
of self-injury that do not mention suicide or suicide attempt, select only the
appropriate self-injury term.
Example
Reported |
LLT Selected |
Comment |
Self slashing |
LLT Self inflicted laceration is linked to
PT Intentional self-injury |
|
Cut her own wrists |
||
Cut wrists in a suicide attempt |
Self inflicted laceration Suicide attempt |
|
Took an overdose in an attempt to commit
suicide |
Intentional overdose Suicide attempt |
If overdose is reported in the context of
suicide or a suicide attempt, the more specific LLT Intentional overdose can be selected (see also Section 3.18) |
If a
suicide attempt is fatal, select the term that reflects the outcome instead of
the attempt only.
Example
Reported |
LLT Selected |
Comment |
Suicide attempt resulted in death |
Completed suicide |
Record death as an outcome |
When
conflicting, ambiguous, or vague information is reported, term selection to support
appropriate data retrieval may be difficult. When this occurs, attempt to
obtain more specific information. If clarification cannot be achieved, select
terms as illustrated in the examples below (Sections 3.4.1 through 3.4.3).
Example
Reported |
LLT Selected |
Comment |
Hyperkalaemia with a serum potassium of 1.6
mEq/L |
Serum potassium abnormal |
LLT Serum
potassium abnormal covers both of the reported concepts (note: serum
potassium of 1.6 mEq/L is a low result,
not high) |
Example
Reported |
LLT Selected |
Comment |
GU pain |
Pain |
Effort should be made to obtain clarification
of the meaning of "GU" from the source so that more specific term selection
may be possible. GU could be either genito-urinary or gastric ulcer . If
additional information is not available, then select a term to reflect the
information that is known, i.e., LLT Pain |
For
information that is vague, attempt to obtain clarification. If clarification
cannot be achieved, select an LLT that reflects the vague nature of the
reported event.
Example
Reported |
LLT Selected |
Comment |
Turned green |
Unevaluable event |
Turned green reported alone is vague; this
could refer to a patient condition or even to a product (e.g., pills) |
Patient had a medical problem of unclear type |
Ill-defined disorder |
Since it is known that there is some form of
a medical disorder, LLT Ill-defined
disorder can be selected |
A combination term in MedDRA is a single
medical concept combined with additional medical wording that provides
important information on pathophysiology or aetiology. A combination term is an
internationally recognised, distinct and robust medical concept as illustrated
in the examples below.
Example
MedDRA Combination Terms |
PT Diabetic
retinopathy PT Hypertensive
cardiomegaly PT Eosinophilic
pneumonia |
A combination
term may be selected for certain reported ARs/AEs (e.g., a condition due to
another condition), keeping the following points in mind (Note: medical
judgment should be applied):
If a
diagnosis and its characteristic signs or symptoms are reported, select a term
for the diagnosis (see Section 3.1). A MedDRA combination term is not needed in
this instance.
Example
Reported |
LLT Selected |
Chest pain due to myocardial infarction |
Myocardial infarction |
If two
conditions are reported in combination, and one is more specific than the
other, select a term for the more specific condition.
Example
Reported |
LLT Selected |
Hepatic function disorder (acute hepatitis) |
Hepatitis acute |
Arrhythmia due to atrial fibrillation |
Atrial fibrillation |
If two
conditions or concepts are reported in combination, and a single MedDRA combination
term is available to represent them, select that term.
Example
Reported |
LLT Selected |
Retinopathy due to diabetes |
Diabetic retinopathy |
Rash with itching |
Itchy rash |
Breast cancer (HER2 positive) |
HER2 positive breast cancer |
If splitting the reported
ARs/AEs provides more clinical information, select more than one MedDRA term.
For example, in the field of oncology, there may be situations in which it is
important to capture information not only for the tumour type, but also for the
associated genetic marker or abnormality because of the implications for
aetiology, prognosis or treatment. If a combination term that describes a
genetic marker or abnormality associated with a medical condition is not
available, separate terms may be selected to represent the genetic marker or
abnormality as well as the associated medical condition.
Example
Reported |
LLT Selected |
Diarrhoea and vomiting |
Diarrhoea Vomiting |
Wrist fracture due to fall |
Wrist fracture Fall |
BRAF positive malignant melanoma |
BRAF gene mutation Malignant melanoma |
Exercise
medical judgment so that information is not lost when splitting a reported
term. Always check the MedDRA hierarchy above the selected
term to be sure it is appropriate for the reported information.
Example
Reported |
LLT Selected |
Comment |
Haematoma due to an animal bite |
Animal bite Traumatic haematoma |
LLT Traumatic
haematoma is more appropriate than LLT Haematoma (LLT Traumatic
haematoma links to HLT Non-site
specific injuries NEC and HLT Haemorrhages
NEC while LLT Haematoma links
only to HLT Haemorrhages NEC) |
If an event
is reported along with a pre-existing condition that has not changed, and if there is not an appropriate
combination term in MedDRA, select a term for the event only (see Section 3.9
for pre-existing conditions that have changed).
Example
Reported |
LLT Selected |
Comment |
Shortness of breath due to pre-existing
cancer |
Shortness of breath |
In this instance, shortness of breath is
the event; cancer is the pre-existing condition that has not changed |
Example
Reported |
LLT Selected |
Jaundice in a newborn |
Jaundice of newborn |
Developed psychosis at age 6 years |
Childhood psychosis |
The preferred option is to select a term
for the event and record the age in
the appropriate demographic field.
Alternatively,
select terms (more than one) that together reflect both the age of the patient
and the event.
Example
Reported |
LLT Selected |
Preferred Option |
Pancreatitis |
|
|
Pancreatitis Neonatal disorder |
|
Example
Reported |
LLT Selected |
Skin rash on face |
Rash on face |
Select a
term for the event, rather than a
term that reflects a non-specific condition at the body site; in other words,
the event information generally has
priority.
Example
Reported |
LLT Selected |
Comment |
Skin rash on chest |
Skin rash |
In this instance, there is no
available term for a skin rash on the chest |
However,
medical judgment is required, and sometimes, the body site information should have
priority as in the example below.
Example
Reported |
LLT Selected |
Comment |
Cyanosis at injection site |
Injection site discolouration |
Cyanosis may suggest a generalised
disorder. In this example, selecting LLT Cyanosis
would result in loss of important medical information and
miscommunication. |
If an event
is reported to occur at more than one body site, and if all of those LLTs link
to the same PT, then select a single LLT that most accurately reflects the
event; in other words, the event
information has priority.
Example
Reported |
LLT Selected |
Comment |
Skin rash on face and neck |
Skin rash |
LLT Rash
on face, LLT Neck rash, and LLT Skin rash all link to PT Rash |
Oedema of hands and feet |
Oedema of extremities |
LLT Oedema
hands and LLT Oedematous feet
both link to PT Oedema peripheral.
However, LLT Oedema of extremities
most accurately reflects the event in a single term |
Example
Reported |
LLT Selected |
Comment |
Pneumococcal pneumonia |
Pneumococcal pneumonia |
In this example, the implied anatomic
location is the lung |
Alternatively,
select a term that reflects the anatomic location or select a term that reflects the microorganism-specific
infection. Medical judgment should be used in deciding whether anatomic
location or the microorganism-specific infection should take priority.
Example
Reported |
LLT Selected |
Preferred Option |
Comment |
Klebsiella infection Kidney infection |
|
Represents both microorganism-specific
infection and anatomic location |
|
Kidney infection |
|
Represents location-specific infection |
|
Klebsiella infection |
|
Represents microorganism-specific infection |
Pre-existing
conditions that have changed may be considered ARs/AEs, especially if the
condition has worsened or progressed (see Section 3.5.5 for pre-existing conditions that have not changed, and Section
3.22 for an unexpected improvement of a pre-existing condition).
Ways That Pre-existing Conditions May Be Modified |
Aggravated, exacerbated, worsened Recurrent Progressive |
Select a
term that most accurately reflects the modified condition (if such term exists)
Example
Reported |
LLT Selected |
Exacerbation of myasthenia gravis |
Myasthenia gravis aggravated |
If no such
term exists, consider these approaches:
Example 1: Select a term for the
pre-existing condition and record the modification in a consistent, documented
way in appropriate data fields
Example 2: Select a term for the
pre-existing condition and a second term
for the modification of the condition (e.g., LLT Condition aggravated, LLT Disease
progression). Record the modification in a consistent, documented way in
appropriate data fields.
Example
Examples |
Reported |
LLT Selected |
Comment |
Example 1 |
Jaundice aggravated |
Jaundice |
Record aggravated in a consistent,
documented way. |
Example 2 |
Jaundice aggravated |
Jaundice Condition aggravated |
Record aggravated in a consistent, documented
way. Select terms for the pre-existing condition and the modification. |
To select the most appropriate exposure term
(or terms) from HLT Exposures associated
with pregnancy, delivery and lactation, first determine if the
subject/patient who was exposed is the mother, the child/foetus, or the father.
If the reported verbatim
information does not specify who was exposed, then a general term such as LLT Exposure during pregnancy can be
selected.
In addition, MedDRA includes terms indicating a pregnant or
breastfeeding woman was exposed, which are placed in HLTs other than HLT Exposures associated with pregnancy, delivery and lactation. These terms include e.g., PT Maternal immunisation, PT Maternal
therapy to enhance foetal lung maturity and PT Maternal-foetal therapy, as well as several PTs relating to
pregnancy on contraceptive. Selecting pregnancy/breast-feeding exposure terms may be considered in addition,
depending on the specific circumstances of each case.
If a
pregnancy exposure is reported with clinical consequences, select terms for
both the pregnancy exposure and the clinical consequences.
Example
Reported |
LLT Selected |
Pregnant patient receiving drug X experienced
a pruritic rash |
Maternal exposure during
pregnancy Pruritic rash |
If a
pregnancy exposure report specifically states that there were no clinical
consequences, the preferred option is to select only a term for the
pregnancy exposure. Alternatively, a term for the pregnancy exposure and the
additional LLT No
adverse effect can be selected (see
Section 3.21).
Example
Reported |
LLT Selected |
Preferred Option |
Maternal exposure
during pregnancy |
|
|
Maternal exposure during pregnancy No adverse effect |
|
Select
terms for both the type of exposure and any adverse event(s).
Example
Reported |
LLT Selected |
Pregnant woman taking drug X; foetal
tachycardia noted on routine examination |
Maternal exposure during
pregnancy Foetal tachycardia |
Baby born with cleft palate; father had been
taking drug X before conception |
Paternal drug exposure before
pregnancy Cleft palate |
Nursing newborn exposed to drug X through
breast milk; experienced vomiting |
Drug exposure via breast milk Vomiting neonatal |
Congenital
= any condition present at birth, whether genetically inherited or occurring in utero
(see the MedDRA Introductory Guide).
Select
terms from SOC Congenital, familial and genetic
disorders when the reporter describes the condition as congenital or when
medical judgment establishes that the condition was present at the time of
birth.
Example
Reported |
LLT Selected |
Comment |
Congenital heart
disease |
|
|
Child born with
heart disease |
||
Newborn with phimosis |
Phimosis |
A congenital term is not available but
LLT/PT Phimosis links to primary SOC Congenital, familial and
genetic disorders |
If
information is available indicating that the condition is not congenital or
present at birth, i.e., it is acquired, select the non-qualified term for the
condition, making sure that the non-qualified term does not link to SOC Congenital, familial and genetic disorders. If a non-qualified term is not
available, select the acquired term for the condition.
Example
LLT Selected |
Comment |
|
Developed night blindness in middle age |
Night blindness |
LLT/PT Night blindness links
to primary SOC Eye disorders. Do
not assume the condition is congenital (LLT/PT Congenital night blindness). |
Developed phimosis at age 45 |
Acquired phimosis |
LLT/PT Phimosis should not
be selected because it links to primary SOC Congenital, familial and genetic disorders |
34 year old patient diagnosed with an oesophageal web |
Acquired oesophageal web |
A non-qualified term Oesophageal web is not available. It cannot be assumed
that the condition was present at birth so it is appropriate to select the
acquired term. |
If a
condition is reported without any information describing it as congenital or
acquired, select the non-qualified term for the condition. For conditions or
diseases existing in both congenital and acquired forms, the following
convention is applied in MedDRA: the more common form of the condition/disease
is represented at the PT level without adding a qualifier of either
congenital or acquired .
Example
Reported |
LLT Selected |
Comment |
Pyloric stenosis |
Pyloric stenosis |
|
Hypothyroidism |
Hypothyroidism
is more commonly acquired than congenital; LLT/PT Hypothyroidism links to primary SOC Endocrine disorders |
Due to the
large number of neoplasm types, specific guidance cannot be provided for all
situations. The MedDRA Introductory Guide describes the use and placement of
neoplasm terms and related terms in MedDRA.
Keep in
mind the following points:
Neoplasms Terms in MedDRA |
Cancer and carcinoma are synonyms (see
online MedDRA Concept Descriptions which can be accessed via the Web-Based
Browser and MedDRA Desktop Browser) Tumo(u)r terms refer to neoplasia Lump and mass terms are not
neoplasia |
If the type
of neoplasia is not clear, seek clarification from the reporter. Consult
medical experts when selecting terms for difficult or unusual neoplasms.
Select a
malignancy term only if malignancy is stated by the reporter. Reports of
tumo(u)r events should not be assigned a cancer , carcinoma or another
malignant term unless it is clear that malignancy is present.
Example
Reported |
LLT Selected |
Tumour growing on skin |
Skin tumour |
Cancer growing on tongue |
Malignant tongue cancer |
Terms in
SOC Surgical
and medical procedures are generally not
appropriate for ARs/AEs. Terms in this SOC are not multiaxial. Be aware of the
impact of these terms on data retrieval, analysis, and reporting.
Keep in mind the following points:
If only a
procedure is reported, select a term for the procedure.
Example
Reported |
LLT Selected |
Patient had transfusion of platelets |
Platelet transfusion |
Patient had tonsillectomy in childhood |
Tonsillectomy |
If a
procedure is reported with a diagnosis, the preferred option is to select terms for both the procedure and
diagnosis. Alternatively, select a term only for the diagnosis.
Example
Reported |
LLT Selected |
Preferred Option |
Comment |
Liver transplantation Liver injury |
|
Selecting term for the procedure may indicate
severity of the condition |
|
Liver injury |
|
|
SOC Investigations includes test names with
qualifiers (e.g., increased, decreased, abnormal, normal) and without
qualifiers. Corresponding medical conditions (such as hyper- and hypo-
terms) are in other disorder SOCs (e.g., SOC Metabolism and nutrition disorders).
SOC Investigations is not multiaxial; always
consider the terms in this SOC for data retrieval.
Keep in
mind the following points when selecting terms for results of investigations:
Selecting terms for a medical
condition vs. an investigation result
Example
Reported |
LLT Selected |
Comment |
Hypoglycaemia |
Hypoglycaemia |
LLT Hypoglycaemia
links to SOC Metabolism
and nutrition disorders |
Decreased glucose |
Glucose decreased |
LLT Glucose
decreased links to SOC Investigations |
Unambiguous investigation result
Example
Reported |
LLT Selected |
Comment |
Glucose 40 mg/dL |
Glucose low |
Glucose is clearly below the reference range |
Ambiguous investigation result
Example
Reported |
LLT Selected |
Comment |
His glucose was 40 |
Glucose abnormal |
In this example, no units have been reported.
Select LLT Glucose abnormal if
clarification cannot be obtained |
When investigation
results are reported with a diagnosis, select only a term for the diagnosis if investigation results are consistent
with the diagnosis.
Example
Reported |
LLT Selected |
Comment |
Elevated potassium, K 7.0 mmol/L, and
hyperkalaemia |
Hyperkalaemia |
It is not necessary to select LLT Potassium increased |
When
investigation results are reported with a diagnosis, select a term for the
diagnosis and also select terms for any
investigation results that are not
consistent with the diagnosis.
Example
Reported |
LLT Selected |
Comment |
Alopecia, rash, and elevated potassium 7.0
mmol/L |
Alopecia Rash Potassium increased |
Elevated potassium is not consistent with the
diagnoses of alopecia and rash. Terms for all concepts should be selected. |
Select a
term for each investigation result as reported; do not lump together separate
investigation results under an inclusive term unless reported as such.
Example
Reported |
LLT Selected |
Comment |
Abnormalities of liver function tests |
Abnormal liver function tests |
|
Increased alkaline phosphatase, increased
SGPT, increased SGOT and elevated LDH |
Alkaline phosphatase increased SGPT increased SGOT increased LDH increased |
Select four individual terms for the
investigation results. A single term such as LLT Liver function tests abnormal should not be selected |
Terms in
SOC Investigations without qualifiers are intended to be
used to record test names when entering diagnostic test data in the ICH E2B
electronic transmission standard.
Example
Information/Reported (Verbatim) |
LLT Selected for Test Name |
Comment |
Cardiac output measured |
Cardiac output |
|
Haemoglobin 7.5 g/dL |
Haemoglobin |
LLT Haemoglobin
decreased should not be
selected as it is both a test name and a result* |
* MedDRA is
used only for test names, not test results, in the E2B data elements for
Results of Tests and Procedures
Test name
terms without qualifiers are not intended for use in other data fields
capturing information such as ARs/AEs and medical history. The use of the
Unqualified Test Name Term List is optional and may be used to identify the
inappropriate selection of these terms in data fields other than the test name
data element. It is available for download from the MedDRA and JMO websites.
For the purposes of term selection and analysis
of MedDRA-coded data,
medication errors are defined as any unintentional and preventable event that
may cause or lead to inappropriate medication use or patient harm while the
medication is in the control of the health care professional, patient or
consumer.
The online
Concept Descriptions contain descriptions of the interpretation and use of
certain medication error terms (e.g., Dispensing error ).
For further
information, please refer to Section 3 of the MedDRA Points to Consider
Companion Document which contains detailed examples, guidance, and Questions
and Answers on medication errors (see Appendix, Section 4.2 Links and
References).
Reports of
medication errors may or may not include information about clinical
consequences.
If a
medication error is reported with clinical consequences, select terms for both
the medication error and the clinical consequences.
Example
Reported |
LLT Selected |
Comment |
Patient was administered wrong drug and
experienced hypotension |
Wrong drug administered Hypotension |
|
Because of similar sounding drug names, the
wrong drug was dispensed; as a result, the patient took the wrong drug and
experienced a rash |
Wrong drug dispensed Wrong drug administered Drug name sound-alike Rash |
The originating error (Wrong drug
dispensed) and reported additional or consequent errors and contributing
factors (Drug name sound-alike) stated in the report should all be coded,
while not subtracting or inferring information |
Insulin preparation was given using the wrong
syringe resulting in the administration of an overdose. The patient developed
hypoglycaemia. |
Drug administered in wrong device Accidental overdose Hypoglycaemia |
If an overdose is reported in the context of
a medication error, the more specific term LLT Accidental overdose can be selected (see also Section 3.18) |
Medication
errors without clinical consequences are not ARs/AEs. However, it is important
to record the occurrence or potential
occurrence of a medication error. Select a term that is closest to the
description of medication error reported.
Intercepted medication error: For the purposes of term selection and analysis of MedDRA-coded data,
an intercepted medication error refers to the situation where a medication
error has occurred, but is prevented from reaching the patient or consumer. The
intercepted error term should reflect the stage at which the error occurred,
rather than the stage at which it was intercepted.
If a
medication error report specifically states that there were no clinical
consequences, the preferred option is to select only a term for the
medication error. Alternatively, a term for the medication error and the
additional LLT No
adverse effect can be selected (see
Section 3.21).
Example
Reported |
LLT Selected |
Preferred Option |
Intramuscular formulation
administered by other route |
|
|
Intramuscular formulation
administered by other route No adverse effect |
|
Example
Reported |
LLT Selected |
Comment |
Pharmacist notices that the names of two
drugs look similar and is concerned that this may result in someone getting a wrong drug |
Drug name look-alike Potential for medication error, wrong
drug |
This example is a potential medication error.
LLT Drug name look-alike is a
contributing factor, and LLT Potential for medication error, wrong drug indicates that there is a
potential medication error including the error type. |
The
physician prescribed the wrong dose of the drug; the error was identified at
the time of dispensing |
Intercepted
drug prescribing error Drug
dose prescribing error |
The
intercepted error terms reflect the stage at which the error occurred, which is not necessarily the stage at which it was intercepted. Capture the type of error that was intercepted
and contributing factors when reported. |
The pharmacist dispensed the wrong
drug because of a similar label design but the patient realised the error and
did not take the drug |
Intercepted drug dispensing error Drug label look-alike Wrong drug dispensed |
|
Patient forgot to take his scheduled dose of
drug X |
Forgot to take product |
LLT Forgot
to take product (PT Product dose
omission in error) is an example of an unintentional dose omission/missed
dose. See the Points to Consider Companion Document for additional examples
of the various scenarios of dose omissions. |
Patient's scheduled dose of drug X was not
administered because he was undergoing surgery that day |
Intentional dose omission |
This is an example of an intentional dose
omission/missed dose. It is not a medication error. |
Due to Drug X shortage, patient was unable to
take her medication for a week |
Drug shortage Temporary interruption of therapy |
This event is neither intentional nor a
medication error. Use LLT Temporary
interruption of therapy (PT Therapy
interrupted, HLT Therapeutic
procedures NEC) and capture the specific external factor which caused the
interruption of therapy. |
For the
purposes of term selection and analysis of MedDRA-coded data, a medication
monitoring error is an error that occurs in the process of monitoring the
effect of the medication through clinical assessment and/or laboratory data.
It can also
refer to monitoring errors in following instructions or information pertinent
to the safe use of the medication, such as the specific scenario regarding the
term LLT Documented hypersensitivity to
administered drug in the example below.
Example
Reported |
LLT Selected |
Comment |
Patient with sulfa allergy documented in
patient s medical file is administered a sulfonamide-based drug and
experienced wheezing |
Documented hypersensitivity to
administered drug Wheezing |
This medication error refers to the situation
when a patient is administered a drug that is documented in the patient's
medical file to cause a hypersensitivity reaction in the patient. |
Example
Reported |
LLT Selected |
Comment |
The patient's liver enzymes were measured
every six months instead of the recommended monthly schedule |
Drug monitoring procedure
incorrectly performed |
The monthly monitoring schedule is in the
label for this drug. This is an example of incorrect monitoring of
laboratory tests recommended in the use of a drug. |
Patient taking lithium-based drug did not
have his lithium levels measured |
Therapeutic drug monitoring
analysis not performed |
This is an example of not monitoring the therapeutic
drug level to ensure that it is within the therapeutic range as recommended
in the label for this drug. |
There are
specific medication error situations when the product is prescribed, dispensed,
or co-administered with specific drugs, with specific foods, or to patients
with specific disease states, or genetic variants, and the product label
describes known noxious effects of these interactions. Select a medication
error term for the type of interaction, such as those listed below.
If the
report indicates that this is intentional misuse or intentional off label use,
select the appropriate terms representing the intentional nature of the event.
If the report does not provide information about whether the event was
accidental or intentional, select an appropriate interaction issue term, e.g.,
LLT Labelled drug-drug interaction issue.
Medication Error Terms Labelled
Interactions |
Labelled
drug-drug interaction medication error Labelled
drug-food interaction medication error Labelled
drug-disease interaction medication error Labelled
drug-genetic interaction medication error |
Example
Reported |
LLT Selected |
Comment |
Patient became pregnant whilst taking an
antifungal drug and an oral contraceptive. She was unaware of the interaction
warning in the label. |
Labelled drug-drug interaction medication
error Pregnancy on oral contraceptive |
Product is labelled for this drug-drug
interaction (see also Section 3.20) |
Patient drank grapefruit juice by mistake whilst
taking a calcium channel blocker. |
Labelled drug-food interaction
medication error |
Product is labelled for this drug-food
interaction with grapefruit juice |
Patient with renal failure is accidentally
prescribed a drug that is contraindicated in renal failure |
Labelled drug-disease interaction
medication error Contraindicated drug prescribed |
Product is labelled for this drug-disease
interaction. LLT Contraindicated drug
prescribed provides additional information about the nature of the labelled
interaction medication error and the stage at which the error occurred. |
Patient was inadvertently given a drug that
is contraindicated in patients who are cytochrome P450 2D6 poor metabolisers |
Labelled drug-genetic interaction
medication error Contraindicated drug administered CYP2D6 poor metaboliser status |
Product is labelled for this drug-genetic
variant interaction |
Do not
infer that a medication error has occurred unless specific information is
provided. This includes inferring that extra dosing, overdose, or underdose has
occurred (see Section 3.18).
Example
LLT Selected |
Comment |
|
Patient took only half of the minimum recommended dose in the label |
Underdose |
Based on this report, it is not known whether the underdose is
intentional or accidental. If information is available, select the more
specific LLT Accidental underdose
or LLT Intentional underdose as
appropriate. |
The
principles for Section 3.15.1 (Medication errors) also apply to accidental
exposures.
Example
Reported |
LLT Selected |
Comment |
Child accidentally took grandmother's pills
and experienced projectile vomiting |
Accidental drug intake by child Vomiting projectile |
|
Father applying topical steroid to his arms
accidentally exposed his child to the drug by carrying her |
Accidental exposure to product by child Exposure via skin contact |
The exposure to term captures the agent of
exposure, i.e., a product, and the exposure via term captures the
route/vehicle of exposure, i.e., skin contact |
For the
purposes of term selection and analysis of MedDRA-coded data, occupational
exposure encompasses the chronic exposure to an agent (including therapeutic
products) during the normal course of one's occupation, and could include
additional scenarios in specific regulatory regions. For example, occupational
exposure may additionally relate to a more acute, accidental form of exposure
that occurs in the context of one's occupation. In these regions, occupational
exposure for healthcare workers could be of particular interest.
Example
Reported |
LLT Selected |
Comment |
Physical therapist developed a
photosensitivity rash on hands after exposure to an NSAID-containing pain
relief cream that she applied to a patient |
Occupational exposure via skin
contact with product Photosensitive rash |
|
Pathologist chronically exposed to
formaldehyde developed nasopharyngeal carcinoma |
Occupational exposure to toxic
agent Nasopharyngeal carcinoma |
Exposure to formaldehyde is a known risk
factor for this type of malignancy |
Nurse splashed injectable drug in her own eye
resulting in excessive tearing |
Accidental contact of product
with eye Excess tears |
An alternative term e.g., LLT Occupational exposure to product via eye
could be selected to replace LLT Accidental
contact of product with eye, if applicable to regional requirements where
acute exposures are considered to be occupational exposures |
The
concepts of misuse, abuse and addiction are closely related and can pose
challenges for term selection since the terms may overlap to some extent; the
specific circumstances of each case/reported event may help in consideration
for term selection of these concepts. Medical judgment and regional regulatory
considerations need to be applied.
It may also be useful to consider these
concepts as shown in the table below:
Concept |
Intentional? |
By Whom? |
Therapeutic Use? |
Additional Sections in this
Document |
Misuse |
Yes |
Patient/consumer |
Yes* |
3.16.1 |
Abuse |
Yes |
Patient/consumer |
No |
3.16.2 |
Addiction |
Yes |
Patient/consumer |
No |
3.16.3 |
The concepts
Medication error and Off label use are placed here for comparison reasons: |
||||
Medication
error |
No |
Patient/consumer
or healthcare professional |
Yes |
3.15 |
Off
label use |
Yes |
Healthcare
professional |
Yes |
3.27 |
Select the most
specific term available and always check the MedDRA hierarchy above the
selected term to be sure it is appropriate for the reported information. In
some cases, it may be appropriate to select more than one MedDRA LLT to
represent the reported information.
For the
purposes of term selection and analysis of MedDRA-coded data, misuse is the intentional use for a therapeutic purpose by a patient or
consumer of a product over-the-counter or prescription other than as
prescribed or not in accordance with the authorised product information.
Example
Reported |
LLT Selected |
Patient deliberately took the medication
twice daily instead of once daily |
Intentional misuse in dosing
frequency |
For the purposes
of term selection and analysis of MedDRA-coded data, abuse is the intentional, non-therapeutic use by a patient or
consumer of a product over-the counter or prescription for a perceived
reward or desired non-therapeutic effect including, but not limited to,
getting high (euphoria). Abuse may occur with a single use, sporadic use or
persistent use of the product.
Example
Reported |
LLT Selected |
Comment |
Athlete used anabolic steroid preparation to
enhance performance |
Steroid abuse |
|
Patient occasionally uses opioid product to
get high |
Opioid abuse, episodic use |
|
Patient deliberately ingested the topical
medication for its psychoactive effect |
Drug abuse Intentional use by incorrect route |
LLT Intentional
use by incorrect route (PT Intentional
product use issue) provides additional information about the nature of
the drug abuse |
See Section 3.24.1 and 3.24.2 for additional references to abuse terms
in MedDRA.
For the
purposes of term selection and analysis of MedDRA-coded data, addiction is an overwhelming desire by
a patient or consumer to take a drug for non-therapeutic purposes together with
inability to control or stop its use despite harmful consequences. Addiction
can occur because drug induces physical dependence and consequently a
withdrawal syndrome, but this is not an essential feature; and addiction can
occur because of a desire to experience the drug's psychological, behavioural
or physical effects.
Example
Reported |
LLT Selected |
Patient became dependent on crack cocaine |
Dependence on cocaine |
Patient became addicted to a deliberately
ingested topical medication for its psychoactive effect |
Drug addiction Intentional use by incorrect route |
See Section 3.24.1 for additional references to addict/addiction terms in
MedDRA.
For the
purposes of term selection and analysis of MedDRA-coded data, drug diversion
means that a drug is diverted from legal and medically necessary uses toward
illegal uses.
Example
Reported |
LLT Selected |
Pharmacist stole medications from the
pharmacy and sold them to others for recreational use |
Drug diversion |
The patient sold his controlled drug
prescription to another person |
Drug diversion |
If a report
of transmission of an infectious agent via a product is received, select a term
for the transmission. If the infection is identified, select a second term for
the specific infection; if appropriate, a product quality issue term can also
be selected (see Section 3.28).
Example
Reported |
LLT Selected |
Transmission of an infectious
agent via product Product contamination bacterial Burkholderia cepacia infection Acute rhinitis |
|
Patient received a blood
transfusion and developed Hepatitis C |
Transfusion-transmitted
infectious disease Hepatitis C |
Medical judgment should be used if the reporter
does not explicitly state transmission of an infectious agent via a product but
this could be implied by other data within the report. In this instance, select LLT Suspected
transmission of an infectious agent via product.
Accidental
overdose terms are grouped under HLT Product
administration errors and issues; other overdose terms are grouped under
HLT Overdoses NEC. Toxicity and poisoning terms are grouped under HLT Poisoning and toxicity.
For the purposes of term
selection and analysis of MedDRA-coded data, overdose is more than the maximum
recommended dose (in quantity and/or concentration), i.e., an excessive dose
(see online Concept Descriptions.)
If
overdose, poisoning or toxicity is explicitly reported, select the appropriate
term.
Example
Reported |
LLT Selected |
Comment |
Patient took an overdose |
Overdose |
Based on this report, it is not known whether
the overdose is intentional or accidental. If information is available,
select the more specific LLT Accidental
overdose or LLT Intentional
overdose as appropriate. |
A child was accidentally poisoned when she
ingested a chemical cleaning product |
Accidental poisoning Chemical poisoning |
|
Patient deliberately took an overdose of
analgesic pills to treat his worsening arthritis |
Intentional overdose |
LLT Arthritis aggravated can be selected as the indication for
treatment |
The dose taken was above the recommended
maximum dose in the label |
Overdose |
Based on this report, it is not known whether
the overdose is intentional or accidental. If information is available,
select the more specific LLT Accidental
overdose or LLT Intentional
overdose as appropriate. |
Select
terms for overdose and for clinical consequences reported in association with
an overdose.
Example
Reported |
LLT Selected |
Stomach upset from study drug overdose |
Overdose Stomach upset |
If an
overdose report specifically states that there were no clinical consequences,
the preferred option is to select only a term for the overdose. Alternatively, a
term for the overdose and the additional LLT No adverse effect can be selected (see Section 3.21).
Example
Reported |
LLT Selected |
Preferred Option |
Patient
received an overdose of medicine without any adverse consequences |
Overdose |
|
Overdose No adverse effect |
|
If available,
select a term that reflects both the device-related event and the clinical
consequence, if so reported.
Example
Reported |
LLT Selected |
Patient with a vascular implant developed an
infection of the implant |
Vascular implant infection |
Patient noted the prosthesis caused pain |
Medical device pain |
If there is
no single MedDRA term reflecting the device-related event and the clinical
consequence, select separate terms for both.
Example
Reported |
LLT Selected |
Ventricular tachycardia due to malfunction of
device |
Device malfunction Ventricular tachycardia |
Partial denture fractured leading to tooth
pain |
Dental prosthesis breakage Tooth pain |
If a device-related
event is reported in the absence of clinical consequences, select the
appropriate term.
Example
Reported |
LLT Selected |
Medical device breakage |
Device breakage |
My patch is leaking on my arm |
Leaking patch |
This term
includes reactions between drugs and other drugs, food, devices and alcohol. In
this document, drug includes biologic products.
Labelled
drug interactions may be medication errors (see Section 3.15.1.3).
Select an
interaction term and additional term(s) for any reported medical event.
Example
Reported |
LLT Selected |
Torsade de pointes with suspected drug interaction |
Drug interaction Torsade de pointes |
Patient drank cranberry juice which interacted
with anticoagulant drug causing an INR increase |
Food interaction INR increased |
Two
products may be used together, but if the reporter does not specifically state
that an interaction has occurred, select terms only for the medical events
reported.
Example
Reported |
LLT Selected |
Patient was started on an anti-seizure
medication and a heart medication and developed syncope |
Syncope |
Patient was already on an anti-seizure medication
and was started on a heart medication, and anti-seizure medication levels
increased |
Anticonvulsant drug level
increased |
LLT No adverse effect can be used when absence
of an AR/AE is specifically reported, despite exposure to a product (see
Sections 3.15.1.2 and 3.18.2).
Some
organisations may want to record LLT No
adverse effect for administrative purposes (e.g., pregnancy registries,
overdose and medication error reports).
Terms for
normal states and outcomes can be used as needed.
Examples of Terms for Normal States and Outcomes |
Sinus rhythm Normal baby Normal electrocardiogram |
Some organisations
may want to record reports of a beneficial effect of a product apart from the
reason it had been given. (Such effects are not usually considered ARs/AEs).
Example
Reported |
LLT Selected |
A bald patient was pleased that he grew hair while
using an antihypertensive product |
Unexpected beneficial therapeutic response Hair growth increased |
It is
important to record modification of effect (e.g., increased, prolonged)
although it is not always an AR/AE.
The preferred option is to select only the
lack of effect term even if consequences are also reported. However, terms
may also be selected for events associated with the lack of effect.
Example
Reported |
LLT Selected |
Preferred Option |
Patient
took drug for a headache, and her headache didn't go away |
Drug ineffective |
|
Drug ineffective Headache |
|
|
Antibiotic didn't work |
Lack of drug effect |
|
Drug ineffective |
|
|
Drug ineffective Deep vein thrombosis leg |
|
Example
Reported |
LLT Selected |
Comment |
AIDS patient taking anti-HIV drug died |
Death |
Do not assume lack of effect in this instance.
Select only a term for death (see Section 3.2). |
Example
Reported |
LLT Selected |
Patient had increased effect from drug A |
Increased drug effect |
Patient had decreased effect from drug A |
Drug effect decreased |
Patient had prolonged effect from drug A |
Drug effect prolonged |
Terms in
SOC Social circumstances represent
social factors and may be suitable to record social and medical history data.
Such terms are not generally suitable for recording ARs/AEs; however, in
certain instances, terms in SOC Social
circumstances are the only available terms for recording ARs/AEs or may add
valuable clinical information.
Example
Reported |
LLT Selected |
Patient's ability to drive was impaired |
Impaired driving ability |
Terms in
SOC Social circumstances are not
multiaxial and, unlike terms in other disorder SOCs in MedDRA (e.g., SOC Gastrointestinal disorders), they
generally refer to a person, not to
a medical condition.
Be aware of
the impact that terms in SOC Social
circumstances may have on data retrieval, analysis and reporting as
illustrated in the table below:
Term in SOC Social circumstances ( person ) |
Similar term in Disorder
SOC ( condition ) |
Alcoholic |
Alcoholism |
Drug abuser |
Drug abuse |
Drug addict |
Drug addiction |
Glue sniffer |
Glue sniffing |
Smoker |
Nicotine dependence |
Note that abuse
terms not associated with drugs/substances are in this SOC, regardless of
whether they refer to the person or to the condition, as illustrated in the
table below:
LLT |
PT |
Child abuse |
|
Child abuser |
|
Elder abuse |
|
Elder abuser |
(See
Section 3.24.2 concerning illegal/criminal acts.)
Terms for
illegal acts of crime and abuse (excluding those related to drug/substance
abuse) are in SOC Social circumstances,
such as LLT Physical assault.
LLTs
representing the perpetrator are
linked to PTs describing the unlawful act committed. PTs representing the victim of unlawful acts generally begin
with Victim of .
Example
Reported |
LLT Selected |
Comment |
Patient's history indicates that patient is a
known sexual offender |
Sexual offender |
Perpetrator; LLT Sexual offender links to
PT Sexual abuse in SOC Social circumstances |
Patient was a childhood sexual assault victim |
Childhood sexual assault victim |
Victim;
LLT Childhood sexual assault victim
links to PT Victim of sexual abuse
in SOC Social circumstances |
Example
Reported |
LLT Selected |
History of gastrointestinal bleed and
hysterectomy |
Gastrointestinal bleed Hysterectomy |
Patient is a cigarette smoker with coronary
artery disease |
Cigarette smoker Coronary artery disease |
Indications
can be reported as medical conditions, prophylaxis of conditions, replacement
therapies, procedures (such as anaesthesia induction) and verbatim terms such
as anti-hypertension . Terms from almost any MedDRA SOC including SOC Investigations may be selected to
record indications.
Regulatory
authorities may have specific requirements for certain aspects of term
selection for indications (e.g., for indications within regulated product
information). Please refer to the regulatory authority's specific guidance for
such issues.
Example
Reported |
LLT Selected |
Hypertension |
|
Anti-hypertensive |
|
Chemotherapy for breast cancer |
Breast cancer |
I took it for my cold symptoms |
Cold symptoms |
If the only
information reported is the type of therapy, select the most specific term.
Example
Reported |
LLT Selected |
Patient received chemotherapy |
Chemotherapy |
Patient received antibiotics |
Antibiotic therapy |
It may not
be clear if the reported indication is a medical condition or a desired outcome
of therapy. The term selected in either case may be the same.
Example
Reported |
LLT Selected |
Comment |
Weight loss |
Weight loss |
Unclear if the purpose is to induce weight
loss or to treat an underweight patient |
Immunosuppression |
Immunosuppression |
Unclear if the purpose is to induce or to
treat immunosuppression |
Term
selection for some indications (e.g., in regulated product information) may be complex
and require selection of more than one LLT to represent the information
completely, depending on the circumstances.
Example
Reported |
LLT Selected |
Comment |
Treatment of aggression in autism |
Aggression |
|
Treatment of chronic iron overload in
thalassaemia major |
Chronic iron overload |
|
Prevention of atherothrombotic events in
patients with myocardial infarction |
Atherothrombosis prophylaxis |
For indications that describe a genetic marker or abnormality associated
with a medical condition, select a combination term that represents both
concepts, if available. See also examples in Section 3.5 Combination Terms.
Example
Reported |
LLT Selected |
Non small cell lung cancer with K‑ras mutation |
Non-small cell lung cancer K-ras gene mutation |
When an indication
for prevention or prophylaxis is reported, select the specific MedDRA term, if
it exists (Note: the words prevention and prophylaxis are synonymous in the
context of MedDRA).
Example
Reported |
LLT Selected |
Prophylaxis of arrhythmia |
Arrhythmia prophylaxis |
Prevention of migraine |
Migraine prophylaxis |
If there is
no MedDRA term containing prevention or prophylaxis , choose one of the
following options. The preferred option
is to select a general prevention/ prophylaxis term and a term for the condition. Alternatively, select a term for the
condition alone or a
prevention/prophylaxis term alone.
Example
Reported |
LLT Selected |
Preferred Option |
Comment |
Prevention Hepatotoxicity |
|
Represents both the prevention/prophylaxis
concept and the condition |
|
Hepatotoxicity |
|
Represents the condition |
|
Prevention |
|
Represents the prevention/prophylaxis concept |
Select the appropriate
term if the product is indicated for performing a procedure or a diagnostic
test.
Example
Reported |
LLT Selected |
Induction of anaesthesia |
Induction of anaesthesia |
Contrast agent for angiogram |
Angiogram |
Contrast agent for coronary angiogram |
Coronary angiogram |
Terms for
supplemental and replacement therapies are in SOC Surgical and medical procedures (see Section 3.13). If the product
indication is for supplementation or replacement therapy, select the closest
term.
Example
Reported |
LLT Selected |
Testosterone replacement therapy |
Androgen replacement therapy |
Prenatal vitamin |
Vitamin supplementation |
If clarification
cannot be obtained, select LLT Drug use
for unknown indication.
Example
Reported |
LLT Selected |
Aspirin was taken for an unknown indication |
Drug use for unknown indication |
For the purposes
of term selection and analysis of MedDRA-coded data, the concept of off label
use relates to situations where a healthcare professional intentionally
prescribes, dispenses, or recommends a product for a medical purpose not in
accordance with the authorised product information (Consider also the table in
Section 3.16). Off-label use terms should only
be selected when off label use is specifically mentioned in the reported
verbatim information. For information that is suggestive of off-label use but
not reported, attempt to obtain clarification. If clarification cannot be
obtained, do not infer that off-label use occurred. When recording off label
use, consider that product information and/or regulations/requirements may
differ between regulatory regions.
If a medical condition/indication is reported along with off label use , the preferred option is to select terms for
the medical condition/indication and off label use. Alternatively, select a
term for the medical condition/indication alone. Select LLT Off label use
alone only if it is the only
information available.
Example
Reported |
LLT Selected |
Preferred Option |
Off label use in unapproved indication Hypertension |
|
|
Hypertension |
|
Example
Reported |
LLT Selected |
Used off label |
Off label use |
Example
Reported |
LLT Selected |
Comment |
Drug approved for use in combination with
drug A was used off label in combination with drug B |
Off label use Drug use for unapproved combination |
LLT Drug
use for unapproved combination provides additional information about the
specific type of off label use. The term is not an off label use term or a
medication error term; it is a general term that can be used in combination
with other terms to capture detail about off label use, misuse, medication
errors, etc. |
If an AR/AE occurs in the setting of off label
use for a medical condition/indication, the preferred option is to select a term for off label use, and a term for the medical
condition/indication in addition to a term for the AR/AE. Alternatively, select
a term for the medical condition/indication and a term for the AR/AE.
Example
Reported |
LLT Selected |
Preferred Option |
Patient was administered a drug off label for pulmonary hypertension
and suffered a stroke |
Off label use in
unapproved indication Pulmonary
hypertension Stroke |
|
Pulmonary hypertension Stroke |
|
It
is important to recognise product quality issues as they may have implications
for patient safety. They may be reported in the context of adverse events or as
part of a product quality monitoring system.
Product
quality issues are defined as abnormalities that may be introduced during the
manufacturing/labelling, packaging, shipping, handling or storage of the
products. They may occur with or without clinical consequences. Such concepts
may pose a challenge for term selection.
Familiarity
with HLGT Product quality, supply,
distribution, manufacturing and quality system issues (in SOC Product issues) is essential for term
selection. Under this HLGT are categories of specific product quality issues
such as HLT Product packaging issues,
HLT Product physical issues, HLT Manufacturing facilities and equipment
issues, HLT Counterfeit, falsified
and substandard products, etc. Navigating down to the appropriate LLTs from
the MedDRA hierarchy is the optimal approach for term selection.
Explanations
of the interpretations and uses of certain product quality issue terms (e.g.,
Product coating incomplete ) are found in the online MedDRA Concept
Descriptions.
If a product quality issue results in clinical consequences, term(s) for
the product quality issue and the clinical consequences should be selected.
Example
Reported |
LLT Selected |
Comment |
New bottle of drug tablets have unusual
chemical smell that made me nauseous |
Product smell abnormal Nauseous |
|
I switched from one brand to another of my
blood pressure medication, and I developed smelly breath |
Product substitution issue brand to brand Smelly breath |
|
Consumer noted that the toothpaste they had purchased
caused a stinging sensation in the mouth. Subsequent investigation of the
product lot number revealed that the toothpaste was a counterfeit product. |
Product counterfeit Stinging mouth |
|
Patient reported severe burning in his nose
after using nasal drops that had a cloudy appearance. An investigation by the
manufacturer revealed that impurities were found in the batch of nasal drops
and that these had been introduced by a faulty piece of equipment. |
Nasal burning Product appearance cloudy Product impurities found Manufacturing equipment issue |
Specific product defects and issues with
manufacturing systems may be reported subsequently as part of a root cause
analysis |
It is important to capture the occurrence of product quality issues even
in the absence of clinical consequences.
Example
Reported |
LLT Selected |
Sterile lumbar puncture kit received in
broken packaging (sterility compromised) |
Product sterile packaging disrupted |
It is important to distinguish
between a product quality issue and a medication error.
Product quality issues are defined as abnormalities that may be
introduced during the manufacturing/labelling, packaging, shipping, handling or
storage of the products. They may occur with or without clinical consequences.
Medication errors are defined as any unintentional and preventable event
that may cause or lead to inappropriate medication use or patient harm while
the medication is in the control of the health care professional, patient or
consumer.
Explanations
of the interpretations of product quality issue terms are found in the online
Concept Descriptions.
Example
Reported |
LLT Selected |
Comment |
Pharmacist dispensing Drug A inadvertently
attached a product label for Drug B |
Wrong label placed on medication during
dispensing |
Medication error |
The drug store clerk noted that the wrong product
label was attached to some bottles in a shipment of mouthwash |
Product label on wrong product |
Product quality issue |
The mother administered an
underdose of antibiotic because the lines on the dropper were illegible |
Product dropper calibration unreadable Accidental underdose |
Product quality issue and medication error.
If underdose is reported in the context of a medication error, the more
specific LLT Accidental underdose
can be selected. |
The following documents and tools can be found on the MedDRA website: (www.meddra.org):
MedDRA
Term Selection: Points to Consider Condensed Version
MedDRA
Data Retrieval and Presentation: Points to Consider document (also available on
the JMO website: www.pmrj.jp/jmo/)
MedDRA Data Retrieval and Presentation: Points
to Consider Condensed Version
MedDRA
Points to Consider Companion Document (also available on the JMO website:
www.pmrj.jp/jmo/)
MedDRA
Introductory Guide
MedDRA
Change Request Information document
MedDRA
Web-Based Browser *
MedDRA
Mobile Browser*
MedDRA
Desktop Browser
MedDRA
Version Report (lists all changes in new version) *
MedDRA
Version Analysis Tool (compares any two versions) *
Unqualified
Test Name Term List
MedDRA
Best Practices
Transition
Date for the Next MedDRA Version
* Requires
user ID and password to access